For infants and children under age three, one dose of nasal influenza vaccine reduces the risk of getting sick with the flu, but two doses offer better protection, reports a study in the May issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.

Led by Dr. Humberto Bracco Neto of Federal University of São Paulo, Brazil, the new study adds to the evidence that the nasal live attenuated influenza vaccine (LAIV) is safe and effective in reducing the risk of influenza—as well as accompanying ear infections—in infants and young children.

Data Support Increased Use of Nasal Influenza Vaccine in Young Children
The study included 3,200 children, aged six months to three years, in South Africa, Brazil, and Argentina. In the first year of the study, the children were randomly assigned to receive one or two doses of LAIV, or to receive inactive placebo vaccines. In the second year, they received one dose of either LAIV or placebo.

Either one or two doses of nasal flu vaccine reduced the children’s risk of becoming ill with influenza. Compared to children receiving placebo vaccine, protection against similar strains of influenza virus was 74 percent for children receiving two doses of LAIV and 58 percent for those receiving one dose. Protection rates remained high during the second year—but somewhat higher for children who received one more dose of LAIV during year 2.

As in previous studies, LAIV caused few complications or side effects. Among children receiving the nasal flu vaccine, the rate of adverse reactions was not significantly higher than for children receiving the inactive placebo.

Middle Ear Infections Decrease As Well
At least in the first year, children receiving LAIV were also less likely to develop middle ear infections (acute otitis media)—a common complication of influenza in young children. Influenza vaccination did not reduce the risk of lower respiratory infections, such as pneumonia.

Influenza is a major cause of illness, doctor visits, and hospitalization in infants and young children. Beginning in the 2008-09 flu season, U.S. recommendations call for two doses of influenza vaccine for all children aged six to eighteen months. However, vaccine recommendations aren’t always easy to meet—it is estimated that less than half of patients receive the recommended two doses. That makes it important to know how much protection is afforded by a single dose of flu vaccine.

Consistent with previous studies, the new results suggest that even a single dose of nasal influenza vaccine provides good protection against influenza in infants and toddlers. In the first year, two doses of LAIV are more effective than a single dose. Protection lasts into the next year as well, although risk of influenza is lower if vaccination is repeated.

One or two doses of LAIV also appears to reduce the risk of middle-ear infections, whether or not the child develops influenza. Like any flu vaccine, LAIV is most effective against closely related influenza strains.

The results show “clinically significant protection” against influenza with even a single nasal dose of LAIV, the researchers conclude. The data on safety and effectiveness support the increased use of LAIV to prevent influenza in infants and young children.

About The Pediatric Infectious Disease Journal
The Pediatric Infectious Disease Journal® is a peer-reviewed, multidisciplinary journal directed to physicians and other health care professionals who manage infectious diseases of childhood. The journal delivers the latest insights on all aspects of infectious disease in children, from state-of-art diagnostic techniques to the most effective drug therapies and other essential treatment protocols. The Pediatric Infectious Disease Journal is official journal of the Pediatric Infectious Diseases Society and the European Society for Paediatric Infectious Diseases.

About Lippincott Williams & Wilkins
Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services. LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.

Wolters Kluwer Health is a division of Wolters Kluwer, a leading global information services and publishing company. The company provides products and services for professionals in the health, tax, accounting, corporate, financial services, legal, and regulatory sectors. Wolters Kluwer had 2008 annual revenues of €3.4 billion ($4.9 billion), employs approximately 20,000 people worldwide, and maintains operations in over 35 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Amsterdam, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.

Source: Wolters Kluwer Health: Lippincott Williams & Wilkins